Key Drivers
- Cash Generation
- High Leverage
- Premium Valuation
AIAI Summary
AMGN is shifting from a mature patent-cliff biotech to a cash-generative transition story, but the stock now hinges on whether newer growth drivers like Repatha, TEZSPIRE, TEPEZZA, and MariTide can outpace denosumab erosion and justify the current valuation while leverage and litigation remain meaningful overhangs.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Generation
- •High Leverage
- •Premium Valuation
AMGN is a highly profitable, cash-generative pharma company with solid liquidity and interest coverage, but its heavy leverage, thin equity cushion, and rich valuation temper the investment case.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Resistance reclaimed
- •Stretched momentum
Over the last month, AMGN broke above the $361–$362 area, posted higher lows, and is in a constructive short-term uptrend, though the sharp recent move leaves it open to a near-term pause or pullback.
Sharp selloff to $337.60 before a fast breakout suggests elevated short-term volatility
Sentiment & News
Key News Insights:
- •Pipeline diversification
- •Biosimilar growth
- •Valuation pressure
Amgen headlines in 2026 centered on a strong but imperfect growth story, with new products and biosimilars offsetting patent and competition pressures while valuation and volatility stayed in focus.
The stock looks supported by multiple growth drivers, but upside may be capped until investors get clearer proof that new products can fully offset LOE and pricing risks
Similar Companies in Healthcare
Other companies in the same sector with AI ratings